Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.
Financial Results:
Granules India Ltd reported Revenues for Q4FY24 of ₹1,176.00 Crores down from ₹1,196.00 Crore year on year, a fall of 1.67%.
Total Expenses for Q4FY24 of ₹1,002.00 Crores down from ₹1,035.00 Crores year on year, a fall of 3.19%.
Consolidated Net Profit of ₹130.00 Crores up 8.33% from ₹120.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹5.35, up 8.30% from ₹4.94 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.